Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ioannis Pyrousis"'
Autor:
Arezina Kasti, Maroulla Nikolaki, Kalliopi Synodinou, Konstantinos Katsas, Konstantinos Petsis, Sophia Lambrinou, Ioannis Pyrousis, Konstantinos Triantafyllou
Publikováno v:
Microorganisms. 10(4)
Stevia, a zero-calorie sugar substitute, is recognized as safe by the Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA). In vitro and in vivo studies showed that stevia has antiglycemic action and antioxidant effects in
Autor:
Kalliopi D. Synodinou, Ioannis Pyrousis, Konstantinos Triantafyllou, Arezina N. Kasti, Maroulla D. Nikolaki
Publikováno v:
Microorganisms, Vol 9, Iss 2376, p 2376 (2021)
Microorganisms
Microorganisms
Inflammasomes are cytoplasmic multiprotein complexes formed by the host’s immune system as a response to microbial infection and cellular damage. Many studies have revealed various regulators of NOD-, LRR-, and pyrin domain-containing protein 3 (NL
Autor:
Ioannis Pyrousis, Konstantinos Triantafyllou, Arezina N. Kasti, Kalliopi D. Synodinou, Maroulla D. Nikolaki, Nikolaos Oikonomopoulos
Publikováno v:
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral NutritionREFERENCES. 37(2)
Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is a rare, inherited, multisystemic autosomal recessive disorder caused by mutations in the nuclear TYMP gene. This syndrome is characterized by ptosis, external ophthalmoplegia, gastrointest
Autor:
Foteinos-Ioannis D. Dimtrakopoulos, Petros Christopoulos, Mariam Elshiaty, Lea Daniello, Ioannis Pyrousis, Anastasia E Kottorou, Thomas Makatsoris, Haralabos Kalofonos, Angelos Koutras
Publikováno v:
Journal of Clinical Oncology. 40:e21096-e21096
e21096 Background: Ιmmune checkpoint inhibitors (ICIs) have tremendously changed the daily clinical practice on the treatment of advanced non-small cell lung cancer (aNSCLC). However, clinical useful biomarkers remain an unmet need. Recently, a new
Autor:
Fotini Kalofonou, Angelos Koutras, Foteinos-Ioannis Dimitrakopoulos, Ioannis Pyrousis, Achilleas Nikolakopoulos, Haralabos P. Kalofonos, Theodora Frantzi, Thomas Makatsoris, Elias Liolis, Anastasia E. Kottorou
Publikováno v:
Cancers
Volume 12
Issue 5
Cancers, Vol 12, Iss 1257, p 1257 (2020)
Volume 12
Issue 5
Cancers, Vol 12, Iss 1257, p 1257 (2020)
Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgr
Autor:
Anastasia E. Kottorou, Achilleas Nikolakopoulos, Haralabos P. Kalofonos, Angelos Koutras, Thomas Makatsoris, Elias Liolis, Foteinos-Ioannis Dimitrakopoulos, Ioannis Pyrousis, Theodora Frantzi, Foteini Kalofonou
Publikováno v:
Journal of Clinical Oncology. 38:e21507-e21507
e21507 Background: With the exception of programmed death ligand 1 (PD-L1) expression and Tumour Mutational Burden (TMB), which have entered clinical practice, no other clinically useful predictive biomarker for immune checkpoint inhibitors (ICIs) ha
Autor:
Kasti, Arezina, Nikolaki, Maroulla, Pyrousis, Ioannis, Synodinou, Kalliopi, Oikonomopoulos, Nikolaos, Triantafyllou, Konstantinos
Publikováno v:
Nutrition in Clinical Practice; Apr2022, Vol. 37 Issue 2, p361-365, 5p
Autor:
Dimitrakopoulos, Foteinos-Ioannis1,2 (AUTHOR) agathonisiotisa@yahoo.gr, Nikolakopoulos, Achilleas1 (AUTHOR) achylles@otenet.gr, Kottorou, Anastasia2 (AUTHOR) ioannis.pyrousis@upnet.gr, Kalofonou, Fotini3 (AUTHOR) kalfotini@gmail.com, Liolis, Elias1 (AUTHOR) lioliselias@yahoo.gr, Frantzi, Theodora1 (AUTHOR) theodorafrantzi@gmail.com, Pyrousis, Ioannis2 (AUTHOR), Koutras, Angelos1 (AUTHOR) angkoutr@otenet.gr, Makatsoris, Thomas1 (AUTHOR) maktom@yahoo.com, Kalofonos, Haralabos1,2 (AUTHOR) kalofonos@upatras.gr
Publikováno v:
Cancers. May2020, Vol. 12 Issue 5, p1257. 1p.